Hepatocyte divalent metal‐ion transporter‐1 is dispensable for hepatic iron accumulation and non‐transferrin‐bound iron uptake in mice

Chia‐Yu Wang, Mitchell D. Knutson – 19 March 2013 – Divalent metal‐ion transporter‐1 (DMT1) is required for iron uptake by the intestine and developing erythroid cells. DMT1 is also present in the liver, where it has been implicated in the uptake of transferrin‐bound iron (TBI) and non‐transferrin‐bound iron (NTBI), which appears in the plasma during iron overload. To test the hypothesis that DMT1 is required for hepatic iron uptake, we examined mice with the Dmt1 gene selectively inactivated in hepatocytes (Dmt1liv/liv).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma

Kai Wang, Ho Yeong Lim, Stephanie Shi, Jeeyun Lee, Shibing Deng, Tao Xie, Zhou Zhu, Yuli Wang, David Pocalyko, Wei Jennifer Yang, Paul A. Rejto, Mao Mao, Cheol‐Keun Park, Jiangchun Xu – 18 March 2013 – Cancer is a genetic disease with frequent somatic DNA alterations. Studying recurrent copy number aberrations (CNAs) in human cancers would enable the elucidation of disease mechanisms and the prioritization of candidate oncogenic drivers with causal roles in oncogenesis.

Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?

Ryan M. Kwok, Dawn M. Torres, Stephen A. Harrison – 16 March 2013 – Vitamin D is a secosteroid with known effects on calcium homeostasis that has recently been shown to have other significant functions regarding immune modulation, cell differentiation and proliferation, and the inflammatory response. As our understanding of the many functions of vitamin D has grown, the presence of vitamin D deficiency (VDD) has become more evident in Western populations. Concomitantly, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease.

Signal regulatory protein α is associated with tumor‐polarized macrophages phenotype switch and plays a pivotal role in tumor progression

Yu‐fei Pan, Ye‐xiong Tan, Min Wang, Jian Zhang, Bo Zhang, Chun Yang, Zhi‐wen Ding, Li‐wei Dong, Hong‐yang Wang – 16 March 2013 – Macrophages (Mψ) are the major component of infiltrating leukocytes in tumors and exhibit distinct phenotypes according to the microenvironment. We have recently found that signal regulatory protein α (SIRPα), the inhibitory molecule expressed on myeloid cells, plays a critical role in controlling innate immune activation.

Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation‐associated liver carcinogenesis in mice

Tobias Pusterla, Julia Nèmeth, Ilan Stein, Lars Wiechert, David Knigin, Silke Marhenke, Thomas Longerich, Varun Kumar, Bernd Arnold, Arndt Vogel, Angelika Bierhaus, Eli Pikarsky, Jochen Hess, Peter Angel – 16 March 2013 – The receptor for advanced glycation endproducts (RAGE) is a multiligand receptor and member of the immunoglobulin superfamily.

PROX1 promotes hepatocellular carcinoma metastasis by way of up‐regulating hypoxia‐inducible factor 1α expression and protein stability

Yanfeng Liu, Ju‐Bo Zhang, Yi Qin, Wei Wang, Lili Wei, Yigang Teng, Lei Guo, Bo Zhang, Zhenhai Lin, Jing Liu, Zheng‐Gang Ren, Qing‐Hai Ye, Youhua Xie – 16 March 2013 – Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of death from cancer worldwide. HCC has a very poor prognosis because of tumor invasiveness, frequent intrahepatic spread, and extrahepatic metastasis. The molecular mechanism of HCC invasiveness and metastasis is poorly understood.

Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial)

Elisabetta Bacchi, Carlo Negri, Giovanni Targher, Niccolò Faccioli, Massimo Lanza, Giacomo Zoppini, Elisabetta Zanolin, Federico Schena, Enzo Bonora, Paolo Moghetti – 16 March 2013 – Although lifestyle interventions are considered the first‐line therapy for nonalcoholic fatty liver disease (NAFLD), which is extremely common in people with type 2 diabetes, no intervention studies have compared the effects of aerobic (AER) or resistance (RES) training on hepatic fat content in type 2 diabetic subjects with NAFLD.

Subscribe to